Medical Devices and Point-of-Care Diagnostic Technology
Note
Point-of-care diagnostics decentralise testing to primary health centres and community settings, reducing dependence on centralised laboratories and directly enabling last-mile delivery under Ayushman Bharat and the National Health Mission. Devices are regulated under the Medical Devices Rules, 2017, notified under the Drugs and Cosmetics Act, 1940, with CDSCO applying a risk-based Class A to D classification framework. Tools in scope include rapid antigen kits, glucometers, handheld ECG devices, and AI-assisted imaging systems. The Production Linked Incentive scheme supports domestic manufacturing of these devices.
In the news
Questions on this topic
Consider the following statements regarding the regulatory framework governing single-use medical devices (SUDs) and their reprocessing in India:
- Under India's Medical Devices Rules, 2017, the Central Drugs Standard Control Organisation (CDSCO) is the primary regulatory authority for the classification, licensing and post-market surveillance of medical devices, including the determination of single-use versus reusable designations.
- A single-use device (SUD) labelled by its manufacturer as non-reusable may nonetheless be legally reprocessed and reused in India provided that validated sterilisation protocols, functional testing and patient consent requirements are fulfilled, as these conditions override the original manufacturer's classification.
- The risks associated with reprocessing single-use medical devices include cross-infection, device malfunction and loss of performance — concerns that inform the rationale for regulatory restrictions on SUD reuse.
Which of the statements given above is/are correct?
Explanation
Statement 1 is correct. Under the Medical Devices Rules, 2017, CDSCO (operating under the Ministry of Health and Family Welfare) is the apex regulatory body for medical devices in India, responsible for classification, licensing, quality standards and post-market oversight — including whether a device is designated single-use or reusable. Statement 2 is incorrect as a matter of regulatory principle. In India's device-regulation framework, a manufacturer's single-use designation is a regulatory classification — it cannot simply be overridden at the hospital level by adopting sterilisation protocols, however scientifically robust. The DGHS order explicitly prohibits reuse of SUDs on patient-safety and regulatory-compliance grounds. While the Cardiological Society of India's 2017 consensus document and practitioners advocate for validated reprocessing pathways, this represents a policy demand, not a currently operative legal override. The legal status of a SUD can change only through a formal regulatory process — not unilaterally at the point of care. Statement 3 is correct. The identified risks of reprocessing SUDs — cross-infection due to inadequate decontamination, device malfunction from structural fatigue, and loss of originally designed performance — are well-established in the regulatory and clinical literature and form the core justification for DGHS-level restrictions on SUD reuse.
Your record on this topic
Sign in to see how many of these you have answered, which ones you got wrong, and to practise this topic on its own.
Sign in →